Short-term Effects of Supplemental Oxygen in Patients With IPF
NCT ID: NCT03050255
Last Updated: 2018-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2016-11-30
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Since there are only limited pharmacological treatment options for IPF patients, this study may help to provide novel information about the short-term effects of supplemental oxygen. Furthermore it may help to investigate possibilities to optimize oxygen therapy in order to facilitate patients´ participation in activities of daily life and not at least to improve patients´ quality of life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Effects of Oxygen Supplementation Among IPF Patients
NCT03688334
Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis
NCT02668029
Coping Strategies Within Pulmonary Rehabilitation in Patients With IPF and COPD
NCT04257630
CO2-Patterns During Hyperoxia and Physical Exercise in COPD
NCT04955561
Effect of Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise
NCT00592033
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Exercise-induced desaturation is frequently observed in patients with idiopathic pulmonary fibrosis and predicts poorer outcomes. However, prospective studies with larger sample sizes and those investigating the effect of oxygen on endurance time, oxygen saturation and breathing frequency during walking are lacking. Given that walking is the most important activity of daily life to preserve the maintenance and to participate in social life, we aim to investigate the effects of supplemental oxygen during walking in IPF patients.
The endurance shuttle walk test (ESWT) is a well validated test with high reliability and validity for measuring endurance walking capacity in patients with chronic obstructive pulmonary disease (COPD). The advantage of this test in contrast to the 6-minute walk test is that the ESWT is performed at 85% of the individual maximum that is close to the intensity of typical daily activities. Additionally, by using the ESWT it is possible to determine the maximum duration of exercise and to compare values at isotime (= time point when the shortest of the 3 ESWTs ends), whereas values at the end of different six-minute walk tests (6MWTs) are not comparable in case of different distances.
Aim:
To investigate the short-term effects of supplemental oxygen on endurance capacity during walking (ESWT) in patients with idiopathic pulmonary fibrosis.
Design:
This study is a randomized, controlled, double-blinded cross-over trial. Following an initial incremental shuttle walk test (ISWT) in order to determine the individual maximum walking capacity, patients will perform 3 endurance shuttle walk tests (ESWT) at 85% of the maximal pace. In randomized order, patients will complete one ESWT on 2l/min oxygen, one on 4l/min oxygen and one on medical air (=compressed room air), whereas the patients as well as the investigator will be blinded to the gas mixture provided. All 3 conditions will be provided via nasal cannula. The time between the two ESWTs will be 24 hours in order to give enough time for regeneration. Endurance Walking capacity as measured by the ESWT will be used as the primary outcome.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESWT order 1
Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
1. medical air (MA)
2. Oxygen (2 Liter/min)
3. Oxygen (4 Liter/min)
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
ESWT order 2
Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
1. medical air (MA)
2. Oxygen (4 Liter/min)
3. Oxygen (2 Liter/min)
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
ESWT order 3
Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
1. Oxygen (2 Liter/min)
2. Medical air (MA)
3. Oxygen (4 Liter/min)
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
ESWT order 4
Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
1. Oxygen (2 Liter/min)
2. Oxygen (4 Liter/min)
3. Medical air (MA)
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
ESWT order 5
Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
1. Oxygen (4 Liter/min)
2. Medical air (MA)
3. Oxygen (2 Liter/min)
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
ESWT order 6
Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:
1. Oxygen (4 Liter/min)
2. Oxygen (2 Liter/min)
3. Medical air (MA)
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Medical air
Oxygen (2Liter/min)
Oxygen (4Liter/min)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
* Clinical signs of any cardial comorbidity
* Not able to walk
* Oxygen flow needed during exercise \> 4l/min
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Linde AG
INDUSTRY
Schön Klinik Berchtesgadener Land
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klaus Kenn
Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Klaus Kenn, Prof.
Role: PRINCIPAL_INVESTIGATOR
Schoen Klinik Berchtesgadener Land
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Schoen Klinik Berchtesgadener Land
Schönau am Königssee, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPF-O2-Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.